Refoxy’s discovery platform, F.act finder (FOXO activator finder), delivers molecules that specifically modulate FOXO3 and elicit unique therapeutic effects. The company is developing a pipeline of therapeutics, with an initial focus on fibrotic disorders, particularly IPF.